← Leaderboards
Jonah B. Sacha
Oregon Health & Science University
$34,199,132
Attributed
$47,497,435
Total exposure
23
Grants
20
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7.9M · FY2010–25$10M$7.5M$5M$2.5M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$47,497,435 · 23
By mechanism
R01$38,086,819 · 8
R21$4,027,511 · 9
P01$1,893,333 · 2
R37$1,657,972 · 1
R33$1,457,202 · 1
R42$299,598 · 1
Top collaborators
- Paul Kievit12 shared
- Scott G Hansen7 shared
- Charles T Roberts7 shared
- Aravind Asokan4 shared
- Klaus J Frueh3 shared
- Lishomwa C Ndhlovu1 shared
- David I Watkins1 shared
Most similar at Oregon Health & Science University
Same institution · by research overlap
- Paul Kievit$12,790,994
- Charles T Roberts$5,489,068
- Justin Greene$1,359,279
Others in their field
Top investigators on “Monitor”
- Jeffrey P Krischer · University Of South Florida$631,818,376
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$476,087,269
- Bambra Strokes · Ppd Development Lp$461,655,950
- David Heimbrook · Leidos Biomedical Research, Inc.$367,240,481
- Lawrence Corey · Fred Hutchinson Cancer Center$302,301,802
Research focus
MonitorInfectionMacaca MulattaMacacaCellsViralAntiretroviral TherapyMediatingPlasmaTissuesBaseImmuneHiv InfectionsT-LymphocyteRecording Of Previous EventsHealth PrioritiesNonhuman PrimateVaccinesVirusPreventDoseImmunityResponseGlobal Health
Grant awards (70)
Evolving Novel AAV Vectors for Gene Therapy to Cure HIV$1,943,700
R01 · FY2025 · AI · contact PI
Characterization of Allogeneic T Cells Mediating HIV Cure$1,657,972
R37 · FY2025 · AI · contact PI
A nonhuman primate model of stem cell transplantation to understand determinants of post-transplant SIV clearance$874,173
R01 · FY2025 · AI · contact PI
Non-canonical epitope presentation and antigen processing by MHC-E$697,170
R01 · FY2025 · AI
Effect of estrogen replacement on postmenopausal ART-associated comorbidity and viral latency$570,250
R01 · FY2025 · AG
Project 1: Immunologic and Virologic Characterization of RhCMV/SIV Vaccine-Mediated SIV Replication Arrest Efficacy$426,282
P01 · FY2025 · AI · contact PI
A Solid-Phase, Long-Acting CCR5 Monoclonal Antibody for HIV Transmission$992,151
R01 · FY2024 · AI · contact PI
Evolving Novel AAV Vectors for Gene Therapy to Cure HIV$971,850
R01 · FY2024 · AI · contact PI
A nonhuman primate model of stem cell transplantation to understand determinants of post-transplant SIV clearance$874,173
R01 · FY2024 · AI · contact PI
Effect of estrogen replacement on postmenopausal ART-associated comorbidity and viral latency$818,107
R01 · FY2024 · AG
Non-canonical epitope presentation and antigen processing by MHC-E$701,712
R01 · FY2024 · AI
Project 1: Immunologic and Virologic Characterization of RhCMV/SIV Vaccine-Mediated SIV Replication Arrest Efficacy$400,171
P01 · FY2024 · AI · contact PI
Effect of obesity on HIV pathogenesis, antiretroviral therapy, and metabolic comorbidities$1,286,550
R01 · FY2023 · DK
A Solid-Phase, Long-Acting CCR5 Monoclonal Antibody for HIV Transmission$975,920
R01 · FY2023 · AI · contact PI
Evolving Novel AAV Vectors for Gene Therapy to Cure HIV$971,850
R01 · FY2023 · AI · contact PI
A nonhuman primate model of stem cell transplantation to understand determinants of post-transplant SIV clearance$874,173
R01 · FY2023 · AI · contact PI
Effect of estrogen replacement on postmenopausal ART-associated comorbidity and viral latency$849,284
R01 · FY2023 · AG
Understanding Unconventional CD8+ T cell Responses in Protection from HIV$795,947
R01 · FY2023 · AI · contact PI
Non-canonical epitope presentation and antigen processing by MHC-E$719,468
R01 · FY2023 · AI
Effect of obesity on HIV pathogenesis, antiretroviral therapy, and metabolic comorbidities$693,828
R01 · FY2023 · DK
Project 1: Immunologic and Virologic Characterization of RhCMV/SIV Vaccine-Mediated SIV Replication Arrest Efficacy$530,656
P01 · FY2023 · AI · contact PI
AAV Delivered CCR5 Blockade for Prevention of Mother-to-Child HIV Transmission.$218,750
R21 · FY2023 · AI · contact PI
Post-acute metabolic sequelae of SARS-CoV-2 infection in nonhuman primates$1,286,550
R01 · FY2022 · DK
Evolving Novel AAV Vectors for Gene Therapy to Cure HIV$985,350
R01 · FY2022 · AI · contact PI
A Solid-Phase, Long-Acting CCR5 Monoclonal Antibody for HIV Transmission$945,533
R01 · FY2022 · AI · contact PI
Effect of estrogen replacement on postmenopausal ART-associated comorbidity and viral latency$859,653
R01 · FY2022 · AG
A nonhuman primate model of stem cell transplantation to understand determinants of post-transplant SIV clearance$837,954
R01 · FY2022 · AI · contact PI
Effect of obesity on HIV pathogenesis, antiretroviral therapy, and metabolic comorbidities$824,832
R01 · FY2022 · DK
Project 1: Immunologic and Virologic Characterization of RhCMV/SIV Vaccine-Mediated SIV Replication Arrest Efficacy$536,224
P01 · FY2022 · AI · contact PI
An IL-15 superagonist approach to clear the latent viral reservoir$485,734
R33 · FY2022 · AI · contact PI
AAV Delivered CCR5 Blockade for Prevention of Mother-to-Child HIV Transmission.$248,824
R21 · FY2022 · AI · contact PI
A nonhuman primate model of stem cell transplantation to understand determinants of post-transplant SIV clearance$950,729
R01 · FY2021 · AI · contact PI
A Solid-Phase, Long-Acting CCR5 Monoclonal Antibody for HIV Transmission$930,504
R01 · FY2021 · AI · contact PI
Effect of obesity on HIV pathogenesis, antiretroviral therapy, and metabolic comorbidities$841,023
R01 · FY2021 · DK
Effect of estrogen replacement on postmenopausal ART-associated comorbidity and viral latency$824,709
R01 · FY2021 · AG
Understanding Unconventional CD8+ T cell Responses in Protection from HIV$800,450
R01 · FY2021 · AI · contact PI
An IL-15 superagonist approach to clear the latent viral reservoir$485,734
R33 · FY2021 · AI · contact PI
Understanding Unconventional CD8+ T cell Responses in Protection from HIV$1,146,291
R01 · FY2020 · AI · contact PI
A Solid-Phase, Long-Acting CCR5 Monoclonal Antibody for HIV Transmission$959,550
R01 · FY2020 · AI · contact PI
A nonhuman primate model of stem cell transplantation to understand determinants of post-transplant SIV clearance$946,593
R01 · FY2020 · AI · contact PI
Effect of obesity on HIV pathogenesis, antiretroviral therapy, and metabolic comorbidities$827,788
R01 · FY2020 · DK
An IL-15 superagonist approach to clear the latent viral reservoir$485,734
R33 · FY2020 · AI · contact PI
Learning from the Ebola success: Can a mAb also save lives after yellow fever infection?$299,598
R42 · FY2020 · AI · contact PI
Defining the Impact of Immunodeficiency Virus Infection on Mycobacteria-Specific, Unconventional CD8+ T cells$254,901
R21 · FY2020 · AI · contact PI
A CCR5 Blocking Antibody as HIV Pre-exposure Prophylaxis$208,557
R21 · FY2020 · AI · contact PI
Effect of obesity on HIV pathogenesis, antiretroviral therapy, and metabolic comorbidities$856,702
R01 · FY2019 · DK
Understanding Unconventional CD8+ T cell Responses in Protection from HIV$819,581
R01 · FY2019 · AI · contact PI
A nonhuman primate model of stem cell transplantation to understand determinants of post-transplant SIV clearance$796,277
R01 · FY2019 · AI · contact PI
A CCR5 Blocking Antibody as HIV Pre-exposure Prophylaxis$250,898
R21 · FY2019 · AI · contact PI
An IL-15 superagonist approach to clear the latent viral reservoir$213,626
R21 · FY2019 · AI · contact PI
A universal MHC-E-restricted T cell vaccine for HIV$931,503
R01 · FY2018 · AI · contact PI
Understanding Unconventional CD8+ T cell Responses in Protection from HIV$847,205
R01 · FY2018 · AI · contact PI
A nonhuman primate model of stem cell transplantation to understand determinants of post-transplant SIV clearance$825,078
R01 · FY2018 · AI · contact PI
An IL-15 superagonist approach to clear the latent viral reservoir$262,500
R21 · FY2018 · AI · contact PI
A nonhuman primate model of stem cell transplantation to understand determinants of post-transplant SIV clearance$851,904
R01 · FY2017 · AI · contact PI
A universal MHC-E-restricted T cell vaccine for HIV$832,221
R01 · FY2017 · AI · contact PI
Impact of retroviral infection on non-classical, mycobacteria-specific T cells.$268,590
R21 · FY2017 · AI · contact PI
A universal MHC-E-restricted T cell vaccine for HIV$100,048
R01 · FY2017 · AI · contact PI
A universal MHC-E-restricted T cell vaccine for HIV$829,438
R01 · FY2016 · AI · contact PI
Impact of retroviral infection on non-classical, mycobacteria-specific T cells.$224,839
R21 · FY2016 · AI · contact PI
A universal MHC-E-restricted T cell vaccine for HIV$819,047
R01 · FY2015 · AI · contact PI
An unconventional, effector memory T cell vaccine for influenza$223,620
R21 · FY2015 · AI · contact PI
Graft versus host immunity in SIV clearance following stem cell transplantation.$218,750
R21 · FY2015 · AI · contact PI
An unconventional, effector memory T cell vaccine for influenza$266,343
R21 · FY2014 · AI · contact PI
Graft versus host immunity in SIV clearance following stem cell transplantation.$262,500
R21 · FY2014 · AI · contact PI
Defining non-classical, CMV-induced CD8 T cell responses$218,750
R21 · FY2014 · AI · contact PI
32nd Annual Symposium on NHP Models for AIDS$75,000
R13 · FY2014 · OD · contact PI
Defining non-classical, CMV-induced CD8 T cell responses$246,750
R21 · FY2013 · AI · contact PI
Identifying endogenous retrovirus T cell targets in SIV-infected macaques$216,563
R21 · FY2011 · AI · contact PI
Identifying endogenous retrovirus T cell targets in SIV-infected macaques$222,750
R21 · FY2010 · AI · contact PI